Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.

Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.

Osteoprotegerin, a potent osteoclast activation inhibitor, decreases bone resorption and positively affects bone mineral density. This study examined the association between serum osteoprotegerin levels and bone loss in patients with chronic kidney disease, a condition associated with increased risk...

Full description

Bibliographic Details
Main Authors: Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Seung Hyeok Han, Kyu Hun Choi, Joongyub Lee, Dong Wan Chae, Kook-Hwan Oh, Curie Ahn, Soo Wan Kim, Representatives of the KNOW-CKD Investigator Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5113973?pdf=render

Internet

http://europepmc.org/articles/PMC5113973?pdf=render

Similar Items